Skip to content

Interest Income at other companies

Avanos Medical logo
Avanos MedicalAVNS
$200K-86.7%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$3.71M+66.6%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s interest income?
Pacira BioSciences, Inc. (PCRX) reported interest income of $1.93M in Q1 2026.
How has Pacira BioSciences, Inc.'s interest income changed year-over-year?
Pacira BioSciences, Inc.'s interest income decreased by 72.0% year-over-year, from $6.9M to $1.93M.
What is the long-term trend for Pacira BioSciences, Inc.'s interest income?
Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s interest income has grown at a 124.4% compound annual growth rate (CAGR), from $896K to $22.73M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.